2023 World Conference on Lung Cancer (Posters)-EP07.04. Clinical and Molecular Profile and Risk Factors of Stage IA NSCLC Relapsing after Radical Resection

EP07.04. Clinical and Molecular Profile and Risk Factors of Stage IA NSCLC Relapsing after Radical Resection - PDF(Slides)

Back to course

Pdf Summary

This study aimed to analyze the clinical and molecular profiles, as well as risk factors, for stage IA Non-Small Cell Lung Cancer (NSCLC) that relapse after radical resection surgery. The study included 313 patients, with a mean age of 67.1 years and a slight majority being female. Pathological stage IA2 was the most common. The total recurrence rate was 9.3%, with 16 cases being loco-regional, 10 distant, and 3 cases both loco-regional and distant. The median Disease-Free Survival (DFS) in relapsing patients was 21 months.<br /><br />The study found that DFS was not influenced by gender, age, histology, type of surgery, tumor size, lymphovascular invasion, or EGFR status. However, a smoking history, tumor grade, and ALK rearrangement were significantly associated with DFS. ALK rearrangement was identified as the sole prognostic factor influencing DFS. Smoking history and tumor grade were also found to be risk factors for the development of recurrences.<br /><br />In relapsing patients, the median Overall Survival (OS) was 76 months. Minimally invasive surgery, local recurrence, surgical treatment of the recurrence, and a major response after treatment were associated with better OS. Time to recurrence did not influence OS.<br /><br />The study concludes that recurrence in radically-resected stage IA NSCLC is possible. High-grade cancers are at a higher risk of recurrence, and patients with ALK rearrangement experience the shortest DFS. These patients should follow dedicated follow-up protocols. For patients with recurrence, minimally invasive treatment of the primary cancer, local recurrence treatment, surgical treatment for the recurrence, and a major response after treatment can improve OS.<br /><br />The data for the study was collected from four high-volume European thoracic surgery centers between January 2017 and December 2021. Patients with multifocal ground-glass opacities and those who underwent neoadjuvant therapy or systemic treatments in the three years before NSCLC diagnosis were excluded from the study.

Asset Subtitle

Pietro Bertoglio

Meta Tag

Speaker Pietro Bertoglio

Topic Early-Stage NSCLC: Progress in Pathology

Keywords

stage IA NSCLC

radical resection surgery

recurrence rate

DFS

ALK rearrangement

tumor grade

smoking history

minimally invasive surgery

local recurrence

follow-up protocols